ImmuCell Corporation
ICCC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $26 | $17 | $19 | $19 |
| % Growth | 51.6% | -5.9% | -3.5% | – |
| Cost of Goods Sold | $19 | $13 | $11 | $11 |
| Gross Profit | $8 | $4 | $8 | $9 |
| % Margin | 30% | 25.2% | 41.2% | 45% |
| R&D Expenses | $4 | $4 | $4 | $4 |
| G&A Expenses | $2 | $2 | $2 | $2 |
| SG&A Expenses | $6 | $5 | $5 | $4 |
| Sales & Mktg Exp. | $3 | $3 | $3 | $3 |
| Other Operating Expenses | $0 | $1 | $0 | $0 |
| Operating Expenses | $10 | $10 | $10 | $8 |
| Operating Income | -$2 | -$6 | -$2 | $0 |
| % Margin | -6.2% | -32.9% | -12.4% | 1.3% |
| Other Income/Exp. Net | -$1 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$2 | -$6 | -$2 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$6 | -$2 | -$0 |
| % Margin | -8.1% | -33.1% | -13.4% | -0.4% |
| EPS | -0.26 | -0.75 | -0.32 | -0.01 |
| % Growth | 65.3% | -134.4% | -3,006.8% | – |
| EPS Diluted | -0.26 | -0.75 | -0.32 | -0.01 |
| Weighted Avg Shares Out | 8 | 8 | 8 | 8 |
| Weighted Avg Shares Out Dil | 8 | 8 | 8 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $3 | $2 | $2 |
| EBITDA | $1 | -$3 | $0 | $3 |
| % Margin | 4% | -14.3% | 1.9% | 14% |